Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics will present late-breaking data on lorundrostat at the Endocrine Society’s annual meeting (ENDO 2026) in Chicago. The poster presentation features post-hoc proteomic analysis from the Launch-HTN and Advance-HTN trials, showing that lorundrostat modulates heart failure risk biomarkers in patients with uncontrolled hypertension.
Key figures
- Drug Name
- Lorundrostat
- Half life hours
- 10-12
- Aldosterone reduction
- 40-70%
- Selectivity vs cortisol
- 374-fold
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.